{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:14:06Z","timestamp":1791850446686,"version":"4.3.4"},"reference-count":91,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2019,2,5]]},"DOI":"10.3233\/jpd-181503","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T11:47:48Z","timestamp":1549367268000},"page":"157-171","source":"Crossref","is-referenced-by-count":154,"title":["Semaglutide is Neuroprotective and Reduces \u03b1-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson\u2019s Disease"],"prefix":"10.1177","volume":"9","author":[{"given":"Liping","family":"Zhang","sequence":"first","affiliation":[{"name":"Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LingYu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[{"name":"Department of Second Hospital Neurology, Shanxi medical University, Taiyuan, Shanxi, PR China"},{"name":"Research and Experimental Center, Henan University of Chinese Medicine, Zhengzhou, Henan province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-181503_ref1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.3233\/JPD-181503_ref2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson\u2019s disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181503_ref3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4239\/wjd.v5.i2.128","article-title":"Recent advances in the molecular genetics of type 2 diabetes mellitus","volume":"5","author":"Brunetti","year":"2014","journal-title":"World J\u00a0Diabetes"},{"key":"10.3233\/JPD-181503_ref4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neulet.2008.03.026","article-title":"Association between AKT1 gene and Parkinson\u2019s disease: A Protective haplotype","volume":"436","author":"Papadimitriou","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.3233\/JPD-181503_ref5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"key":"10.3233\/JPD-181503_ref6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.expneurol.2011.06.005","article-title":"Insulin resistance impairs nigrostriatal dopamine function","volume":"231","author":"Morris","year":"2011","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-181503_ref7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00313602","article-title":"Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson\u2019s disease","volume":"87","author":"Moroo","year":"1994","journal-title":"Acta Neuropathol (Berl)"},{"issue":"Suppl 1","key":"10.3233\/JPD-181503_ref8","first-page":"263","article-title":"Insulin and Alzheimer\u2019s disease: Untangling the web.S","volume":"33","author":"Craft","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JPD-181503_ref9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","article-title":"Intranasal insulin as a treatment for Alzheimer\u2019s disease: A Review of basic research and clinical evidence","volume":"27","author":"Freiherr","year":"2013","journal-title":"CNS Drugs"},{"key":"10.3233\/JPD-181503_ref10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: Mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.3233\/JPD-181503_ref11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/XCE.0000000000000087","article-title":"GLP-1 and GIP analogues as novel treatments for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"5","author":"H\u00f6lscher","year":"2016","journal-title":"Cardiovasc Endocrinol"},{"key":"10.3233\/JPD-181503_ref12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/13543784.2011.562191","article-title":"Lixisenatide for type 2 diabetes mellitus","volume":"20","author":"Christensen","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.3233\/JPD-181503_ref13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/BST20140016","article-title":"Insulin, incretins and other growth factors as potential novel treatments for Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"42","author":"H\u00f6lscher","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.3233\/JPD-181503_ref14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.3233\/JPD-181503_ref15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models","volume":"136","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-181503_ref16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer\u2019s disease","volume":"15","author":"Long-Smith","year":"2013","journal-title":"Neuromolecular Med"},{"key":"10.3233\/JPD-181503_ref17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3233\/JAD-2002-4605","article-title":"The glucagon-like peptides: A New genre in therapeutic targets for intervention in Alzheimer\u2019s disease","volume":"4","author":"Perry","year":"2002","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JPD-181503_ref18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease","volume":"86","author":"Bertilsson","year":"2010","journal-title":"J Neurosci Res"},{"key":"10.3233\/JPD-181503_ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JPD-181503_ref20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease","volume":"202","author":"Kim","year":"2009","journal-title":"J Endocrinol"},{"key":"10.3233\/JPD-181503_ref21","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-181503_ref22","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"key":"10.3233\/JPD-181503_ref23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease","volume":"4","author":"Iciar","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-181503_ref24","first-page":"31585","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A Randomised, double-blind, placebo-controlled trial","volume":"6736","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.3233\/JPD-181503_ref25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.3233\/JPD-181503_ref26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.3233\/JPD-181503_ref27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/14728214.9.1.155","article-title":"Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors","volume":"9","author":"Holst","year":"2004","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.3233\/JPD-181503_ref28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.coph.2013.09.005","article-title":"Gut hormones as therapeutic agents in treatment of diabetes and obesity","volume":"13","author":"Tan","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.3233\/JPD-181503_ref29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.3233\/JPD-181503_ref30","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"Mcclean","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-181503_ref31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.3233\/JPD-181503_ref32","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.3233\/JPD-181503_ref33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: First global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.3233\/JPD-181503_ref34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14712598.2018.1439014","article-title":"Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes","volume":"18","author":"Hedrington","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.3233\/JPD-181503_ref35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"10.3233\/JPD-181503_ref36","volume-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2012"},{"key":"10.3233\/JPD-181503_ref37","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","article-title":"Understanding dopaminergic cell death pathways in Parkinson disease","volume":"90","author":"Michel","year":"2016","journal-title":"Neuron"},{"key":"10.3233\/JPD-181503_ref38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.ne.11.030188.000501","article-title":"MPTP toxicity: Implications for research in Parkinson\u2019s disease","volume":"11","author":"Kopin a","year":"1988","journal-title":"Ann Rev Neurosci"},{"key":"10.3233\/JPD-181503_ref39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0304-3940(86)90282-X","article-title":"Histochemistry of MPTP oxidation in the rat brain: Sites of synthesis of thearkinsonism-inducing toxin MPP+","volume":"65","author":"Nakamura","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.3233\/JPD-181503_ref40","first-page":"65","article-title":"The role of MAO in MPTP toxicity\u2014a review","volume":"20","author":"Glover","year":"1986","journal-title":"J Neural Transm Suppl"},{"key":"10.3233\/JPD-181503_ref41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0922-4106(91)90073-Q","article-title":"MPTP mechanisms of neurotoxicity and their implications for Parkinson\u2019s disease","volume":"208","author":"Gerlach","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JPD-181503_ref42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0304-3940(86)90282-X","article-title":"Histochemistry of MPTP oxidation in the rat brain: Sites of synthesis of thearkinsonism-inducing toxin MPP+","volume":"65","author":"Nakamura","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.3233\/JPD-181503_ref43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0197-0186(87)90024-6","article-title":"The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson\u2019s disease","volume":"11","author":"Kinemuchi","year":"1987","journal-title":"Neurochem Int"},{"key":"10.3233\/JPD-181503_ref44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-8993(97)00429-0","article-title":"Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions","volume":"765","author":"Smith","year":"1997","journal-title":"Brain Res"},{"key":"10.3233\/JPD-181503_ref45","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.3233\/JPD-181503_ref46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson\u2019s disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-181503_ref47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci"},{"key":"10.3233\/JPD-181503_ref48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J Mol Neurosci"},{"key":"10.3233\/JPD-181503_ref49","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat Med"},{"key":"10.3233\/JPD-181503_ref50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02741387","article-title":"Tyrosine hydroxylase and Parkinson\u2019s disease","volume":"16","author":"Haavik","year":"1998","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JPD-181503_ref51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.biochem.68.1.355","article-title":"Tetrahydropterin-dependent amino acid hydroxylases [Review]","volume":"68","author":"Fitzpatrick","year":"1999","journal-title":"Ann Rev Biochem"},{"key":"10.3233\/JPD-181503_ref52","first-page":"436813","article-title":"Parkinson\u2019s disease and systemic inflammation","volume":"2011","author":"Ferrari","year":"2011","journal-title":"Parkinsons Dis"},{"key":"10.3233\/JPD-181503_ref53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1742-2094-11-51","article-title":"Inflammation-sleep interface in brain disease: TNF, insulin, orexin","volume":"11","author":"Clark","year":"2014","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JPD-181503_ref54","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1523\/JNEUROSCI.4261-15.2016","article-title":"Pathogenic upregulation of glial lipocalin-2 in the Parkinsonian dopaminergic system","volume":"36","author":"Kim","year":"2016","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-181503_ref55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.ne.11.030188.000501","article-title":"MPTP toxicity: Implications for research in Parkinson\u2019s disease","volume":"11","author":"Kopin","year":"1988","journal-title":"Annu Rev Neurosci"},{"key":"10.3233\/JPD-181503_ref56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.parkreldis.2012.07.002","article-title":"In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson\u2019s disease","volume":"19","author":"Iannaccone","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-181503_ref57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuroscience.2014.10.028","article-title":"Inflammation is genetically implicated in Parkinson\u2019s disease","volume":"302","author":"Dzamko","year":"2015","journal-title":"Neuroscience"},{"key":"10.3233\/JPD-181503_ref58","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ncpneuro0924","article-title":"Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis","volume":"4","author":"Henchcliffe","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"Suppl","key":"10.3233\/JPD-181503_ref59","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/nrn1434","article-title":"Oxidative stress in neurodegeneration: Cause or consequence?","volume":"10","author":"Andersen","year":"2004","journal-title":"Nat Med"},{"key":"10.3233\/JPD-181503_ref60","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1471-4159.2006.03907.x","article-title":"Oxidative stress and neurodegeneration: Where are we now?","volume":"97","author":"Halliwell","year":"2006","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-181503_ref61","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00702-011-0758-7","article-title":"Reactive oxygen\/nitrogen species and their functional correlations in neurodegenerative diseases","volume":"119","author":"Ramalingam","year":"2012","journal-title":"J Neural Transm"},{"key":"10.3233\/JPD-181503_ref62","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2174\/138161211795164095","article-title":"The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A New rodent model to test palliative and neuroprotective agents for Parkinson\u2019s disease","volume":"17","author":"Prediger","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.3233\/JPD-181503_ref63","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","article-title":"D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson\u2019s disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation","volume":"797","author":"Li","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JPD-181503_ref64","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant \u03b1-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.3233\/JPD-181503_ref65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of alpha-synuclein: From structure and toxicity to theraeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JPD-181503_ref66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicellidaley","year":"2011","journal-title":"Neuron"},{"key":"10.3233\/JPD-181503_ref67","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.3233\/JPD-181503_ref68","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1084\/jem.20112457","article-title":"Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice","volume":"209","author":"Luk","year":"2012","journal-title":"J Exp Med"},{"key":"10.3233\/JPD-181503_ref69","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JPD-181503_ref70","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1089\/ars.2011.4074","article-title":"Mitochondria and programmed cell death in Parkinson\u2019s disease: Apoptosis and beyond","volume":"16","author":"Perier","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"10.3233\/JPD-181503_ref71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.3233\/JPD-181503_ref72","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","article-title":"Bcl-2 heterodimerizes} with a conserved homolog, Bax, that accelerates programmed cell death","volume":"74","author":"Oltvai","year":"1993","journal-title":"Cell"},{"key":"10.3233\/JPD-181503_ref73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrm3028","article-title":"Mechanisms of mitophagy","volume":"12","author":"Youle","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.3233\/JPD-181503_ref74","doi-asserted-by":"crossref","first-page":"a006080","DOI":"10.1101\/cshperspect.a006080","article-title":"Cell death signaling","volume":"7","author":"Green","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.3233\/JPD-181503_ref75","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4161\/auto.8.2.18938","article-title":"Alpha-synuclein\u00e2\u2122s degradation in vivo","volume":"8","author":"Ebrahimi-Fakhari","year":"2012","journal-title":"Autophagy"},{"key":"10.3233\/JPD-181503_ref76","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/15548627.2016.1207014","article-title":"Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function","volume":"12","author":"Kim","year":"2016","journal-title":"Autophagy"},{"key":"10.3233\/JPD-181503_ref77","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1523\/JNEUROSCI.0089-14.2015","article-title":"A53T human \u03b1-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration","volume":"35","author":"Chen","year":"2015","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-181503_ref78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2013.10.004","article-title":"Autophagy and apoptosis dysfunction in neurodegenerative disorders","volume":"112","author":"Ghavami","year":"2014","journal-title":"Prog Neurobiol"},{"key":"10.3233\/JPD-181503_ref79","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1101\/cshperspect.a009365","article-title":"Programmed cell death in Parkinson\u2019s disease","volume":"2","author":"Venderova","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.3233\/JPD-181503_ref80","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.18632\/aging.101083","article-title":"Impaired autophagy activity is linked to elevated ER-stress and inflammation in aging adipose tissue","volume":"8","author":"Ghosh","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"10.3233\/JPD-181503_ref81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ncb2021","article-title":"The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1","volume":"12","author":"Komatsu","year":"2010","journal-title":"Nat Cell Biol"},{"key":"10.3233\/JPD-181503_ref82","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1038\/s41598-017-16488-x","article-title":"Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells","volume":"7","author":"Panagaki","year":"2017","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-181503_ref83","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1523\/JNEUROSCI.20-09-03182.2000","article-title":"Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons","volume":"20","author":"Granholm","year":"2000","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-181503_ref84","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nn.2136","article-title":"Absolute requirement of GDNF for adult catecholaminergic neuron survival","volume":"11","author":"Pascual","year":"2008","journal-title":"Nat Neurosci"},{"key":"10.3233\/JPD-181503_ref85","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: A Glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"10.3233\/JPD-181503_ref86","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson\u2019s disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.3233\/JPD-181503_ref87","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1089\/hum.2009.103","article-title":"Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys","volume":"20","author":"Su","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.3233\/JPD-181503_ref88","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson\u2019s disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.3233\/JPD-181503_ref89","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","article-title":"Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-181503_ref90","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","article-title":"A novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson\u2019s disease","volume":"117","author":"Jalewa","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-181503_ref91","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson\u2019s disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur J Pharmacol"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-181503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:46:33Z","timestamp":1777610793000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-181503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,5]]},"references-count":91,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jpd-181503","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,5]]}}}